iNtRON Biotechnology, Inc.
Founded in 1999 and listed on KOSDAQ in 2011, iNtRON Biotechnology develops bacteriophage-based new drugs via its itLysin and IMPA platforms alongside a molecular diagnostics business.
Price
Change
Market cap
Products & technology
- COVID-19 molecular diagnostic kitCOVID-19 diagnosis
- Rapid antigen diagnostic kitInfectious disease diagnosis
- Pneumococcus diagnostic kitPneumococcal infection diagnosis
- Animal antibiotic alternativeReplacement for veterinary antibiotics
Regulatory approvals
data.go.kr25 Korean MFDS device approvals · 2013–2023
- MFDSIVD reagents for extracting nucleic acids2023-09-05Product approval · Class 1체외 제신 23-1339 호
- MFDSIVD reagents for extracting nucleic acids2023-08-30Product approval · Class 1체외 제신 23-1300 호
- MFDSExtractor, nucleic acid2023-08-03Product approval · Class 1체외 제신 23-1197 호
- MFDSIVD reagents for extracting nucleic acids2023-07-14Product approval · Class 1체외 제신 23-1098 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2022-11-17Product approval · Class 3체외 제허 22-771 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2022-02-08Product approval · Class 3체외 제허 22-80 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2021-12-10Product approval · Class 3체외 제허 21-998 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2021-04-05Product approval · Class 3체외 제허 21-252 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2020-07-03Product approval · Class 3체외 제허 20-538 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-04-28Product approval · Class 3체외 제허 20-327 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-04-06Product approval · Class 3체외 제허 20-256 호
- MFDSIVD reagents for extracting nucleic acids2019-10-08Product approval · Class 1체외 제신 19-1315 호
Show 13 more
- MFDSExtractor, nucleic acid2017-06-08Product approval · Class 1체외 제신 17-610 호
- MFDSIVD reagents for extracting nucleic acids2017-02-20Product approval · Class 1체외 제신 17-169 호
- MFDSOther reagents, classⅠ, for molecular diagnosticsRevoked2014-03-13Product approval · Class 1경인 체외 제신 14-211 호
- MFDSOther reagents, classⅠ, for molecular diagnosticsRevoked2014-03-13Product approval · Class 1경인 체외 제신 14-212 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2014-02-12Product approval · Class 3체외 제허 14-395 호
- MFDSOther reagents, classⅠ, for molecular diagnosticsRevoked2014-01-09Product approval · Class 1경인 체외 제신 14-33 호
- MFDSOther reagents, classⅠ, for molecular diagnostics2014-01-09Product approval · Class 1경인 체외 제신 14-34 호
- MFDSOther reagents, classⅠ, for molecular diagnostics2014-01-09Product approval · Class 1경인 체외 제신 14-35 호
- MFDSOther reagents, classⅠ, for molecular diagnostics2014-01-09Product approval · Class 1경인 체외 제신 14-36 호
- MFDSOther reagents, classⅠ, for molecular diagnostics2014-01-09Product approval · Class 1경인 체외 제신 14-37 호
- MFDSOther reagents, classⅠ, for molecular diagnostics2014-01-09Product approval · Class 1경인 체외 제신 14-38 호
- MFDSIVD reagents for extracting nucleic acids2013-08-12Product approval · Class 1경인 체외 제신 13-344 호
- MFDSIVD reagents for Infectious disease marker(Drug resistant microorganism)Revoked2013-04-18Product approval · Class 3체외 제허 13-721 호
Clinical trials
data.go.kr4 MFDS clinical trial authorisations · 2013–2026 (Phase 1 2 · Phase 1/2a 1 · Phase 2 1)
- Phase 1/2aN-Rephasin® SAL2002026-06-08
2 trial sites
- Phase 1N-Rephasin® SAL2002017-08-16
1 trial site
- Phase 2N-Rephasin® SAL2002016-01-06
2 trial sites
- Phase 1N-Rephasin® SAL2002013-01-24
1 trial site
R&D and key agreements
Source: DART corporate disclosureMRSA 대응 API 기반 심내막염 치료제 · 심내막염(Endocarditis) · itLysin platform-based, using MRSA-targeting active pharmaceutical ingredient
황색포도알균 탈집락 제제 · 병원내 감염(황색포도알균) · itLysin platform-based decolonization agent
장내 CRE 탈집락 제제 · 그람음성균 감염(CRE) · itLysin platform-based, using gram-negative-targeting active pharmaceutical ingredient
장내 C. difficile 탈집락 제제 · Clostridioides difficile 감염 · itLysin platform-based decolonization agent
재발성 CDI 치료제 · 재발성 C. difficile 감염(Recurrent CDI) · itLysin platform-based treatment for recurrent CDI
TgC-PhageE · 대장암 면역치료 · First IMPA™ platform candidate, designed via AI analysis to target both pks+ E.coli and its toxin colibactin
비만 치료제 · 비만 · Under development on the IMPA™ platform
퇴행성 뇌질환 치료제 · 퇴행성 뇌질환 · Under development on the IMPA™ platform
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition